Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death

AstraZeneca39,513 enrolled

Overview

The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in first- time users of low dose ASA for secondary prevention using a UK primary care database.

Number of Anticipated Subjects: In case-control analysis 5.000-10.000

Study Type

OBSERVATIONAL

Enrollment

39,513

Conditions

Nonfatal Myocardial Infarction Coronary Death

Eligibility

Sex: ALLMin age: 50 YearsMax age: 84 Years

Medical Language ↔ Plain English

Inclusion Criteria: * As above (study population description). * All individuals aged 50-84 years with at least two year of enrolment with the primary care physician (PCP) and a computerized prescription history of at least one year before the start of the study. Exclusion Criteria: * Recorded diagnosis of cancer prior to study start. * Alcohol abuse or alcohol-related disease prior to study start. * Patients aged ≥ 70 years with a follow-up longer than one year if having fewer than two recorded consultations with a primary care physician (PCP) during their entire follow-up (proxy for incomplete and invalid data recording) which for some individuals will be close to 8 years.

Locations (1)

Research Site

Madrid, Spain

Outcomes

Primary Outcomes

Nonfatal MI or coronary death

Time frame: Up to eight years from entry into study cohort

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.